Price$1.57+0.16 (+11.31%)
2026-03-022026-06-03
News · 26 weeks20+100%
2025-12-072026-05-31
Mix890d
- Other4(50%)
- Dividends3(38%)
- SEC Filings1(13%)
Latest news
25 items- PRJoin BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), the Company's investigational oral drug candidate that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathwa
- PRBioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant lim
- PRBioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's DiseaseCARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last patient evaluation visit has been completed for the Company's SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson's disease. "With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was designed to assess bezisterim's magnitude of therapeutic impact on a s
- SECSEC Form 10-Q filed by BioVie Inc.10-Q - BIOVIE INC. (0001580149) (Filer)
- PRBioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson's disease. To register, click here. The event will provid
- PRBioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual MeetingCARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson's Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 2026. The abstract, titled A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic (J. Palumbo1, C Ahlem1, C.L. Reading1, S. O'Quinn2, J. Zhan
- SECSEC Form SCHEDULE 13D filed by BioVie Inc.SCHEDULE 13D - BIOVIE INC. (0001580149) (Subject)
- PRBioVie Announces Abstract Accepted for Presentation at AD/PD 2026CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson's Disease at the upcoming AD/PD 2026 Advances in Science & Therapy annual meeting, to be held March 17-21, 2026 in Copenhagen, Denmark. The abstract, titled Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson's Disease (SUNRISE-PD) (J. Palumbo1, C Ahlem1, C.L. Rea
- PRJoin Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4CARSON CITY, Nev., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on March 4, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss BioVie's investigational drug candidate bezisterim (NE3107), a first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and Long COVID, where it has shown encouraging signals of improved cogniti
- PRBioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual MeetingCARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer's Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL. The two abstracts have been accepted for presentation as posters during a session to be held on February 18, 2026. Details of the abstracts are as follows: Abstract Title: Bezisterim-Associated Anti-i
- SECSEC Form 10-Q filed by BioVie Inc.10-Q - BIOVIE INC. (0001580149) (Filer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Palumbo Joseph M4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Kim Joanne Wendy4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Rogich Sigmund4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Do Cuong V4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Sherman Michael Edward4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Farag Kameel D.4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Chappell Amy Suzon4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Lang James Paul4 - BIOVIE INC. (0001580149) (Issuer)
- PRBioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim (NE3107) on motor and non-motor symptoms in individuals with early-stage Parkinson's disease (PD) who have not been treated with
- SECSEC Form S-8 filed by BioVie Inc.S-8 - BIOVIE INC. (0001580149) (Filer)
- PRJoin Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie's first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduce
- SECSEC Form EFFECT filed by BioVie Inc.EFFECT - BIOVIE INC. (0001580149) (Filer)
- SECBioVie Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BIOVIE INC. (0001580149) (Filer)
- SECBioVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BIOVIE INC. (0001580149) (Filer)
BIVI FAQ
6 questionsWhat does BioVie Inc. do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and...Where does BIVI stock trade?
BioVie Inc. (BIVI) is listed on NASDAQ.What sector and industry is BIVI in?
BioVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BIVI?
BioVie Inc. has had 2 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $700.00 price target on 2022-07-22. Recent price targets range from $700.00 to $2700.00.What companies are similar to BIVI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BIVI side-by-side with any of them on Quantisnow.How can I track BIVI on Quantisnow?
Quantisnow aggregates BioVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIVI to receive live email and push alerts on every new disclosure.